Alumis (ALMS) Share-based Compensation (2023 - 2026)
Alumis (ALMS) posted quarterly Share-based Compensation of -$236.3 million for Q4 2025, down 3816.59% year-over-year from $6.4 million in Q4 2024, and down 458.03% quarter-over-quarter from $66.0 million in Q3 2025.
Alumis (ALMS) Share-based Compensation (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Share-based Compensation for 3 consecutive years, with -$236.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation fell 3816.59% year-over-year to -$236.3 million; the TTM figure through Dec 2025 stood at -$219.5 million (down 1228.13% YoY), while the FY2025 annual figure was $60.0 million, up 10.29% from the prior year.
- Share-based Compensation retreated to -$236.3 million in Q4 2025 per ALMS's latest filing, from $66.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $66.0 million in Q3 2025 and bottomed at -$236.3 million in Q4 2025.
- Historically, Share-based Compensation has averaged -$1.7 million across 3 years, with a median of $3.1 million in 2024.
- On a YoY basis, Share-based Compensation climbed as much as 2274.86% in 2025 and fell as far as 3816.59% in 2025.
- Alumis' Share-based Compensation stood at $2.6 million in 2023, then jumped by 143.14% to $6.4 million in 2024, then sank by 3816.59% to -$236.3 million in 2025.
- Business Quant data shows ALMS's Share-based Compensation at -$236.3 million in Q4 2025, $66.0 million in Q3 2025, and $62.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Alumis | 3.25 Bn | 2.75 Bn | - | 152.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 152.30 Mn |
| Jun 30, 2026 | 152.30 Mn |
| Dec 31, 2025 | -236.30 Mn |
| Dec 31, 2025 | -236.30 Mn |
| Sep 30, 2025 | 66.00 Mn |
| Sep 30, 2025 | 66.00 Mn |
| Jun 30, 2025 | 62.00 Mn |
| Jun 30, 2025 | 62.00 Mn |
| Mar 31, 2025 | 63.10 Mn |
| Mar 31, 2025 | 63.10 Mn |
| Dec 31, 2024 | 6.36 Mn |
| Dec 31, 2024 | 6.36 Mn |
| Sep 30, 2024 | 7.31 Mn |
| Sep 30, 2024 | 7.31 Mn |
| Jun 30, 2024 | 3.13 Mn |
| Jun 30, 2024 | 3.13 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Dec 31, 2023 | 2.62 Mn |
| Dec 31, 2023 | 2.62 Mn |